Insulet Corp (PODD, Financial) has recently shown a notable daily gain of 5.29% and an impressive three-month gain of 36.9%. With an Earnings Per Share (EPS) of $1.71, investors may question whether the stock is significantly undervalued. This valuation analysis seeks to uncover the true market value of Insulet (PODD) and provide a detailed insight into its financial health and prospects. Read on for a comprehensive exploration of Insulet's intrinsic value as we delve into the company's financials and growth potential.
Company Introduction
Insulet Corp (PODD, Financial), established in 2000, has revolutionized insulin infusion therapy for diabetes with its Omnipod system, a compact and disposable device managed via smartphone. Since its FDA approval in 2005, the Omnipod has become a vital tool for around 360,000 insulin-dependent diabetics globally. When comparing Insulet's current stock price of $218.97 to the Fair Value (GF Value) of $370.63, it appears that the stock may be significantly undervalued. This discrepancy sets the stage for a deeper investigation into Insulet's valuation, blending financial analysis with key company insights.
Summarize GF Value
The GF Value is a unique metric that reflects the intrinsic value of Insulet (PODD, Financial), considering its historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates. The GF Value Line suggests the fair trading price for Insulet's stock. If the stock price is significantly above this line, it may be overvalued, and conversely, if it's below, it could indicate undervaluation and the potential for higher future returns. Currently, with a market cap of $15.30 billion and a stock price of $218.97, Insulet is considered significantly undervalued, which could mean a promising long-term return on investment.
Financial Strength
Assessing a company's financial strength is crucial before investing in its stock. Insulet's cash-to-debt ratio stands at 0.47, which is lower than 75% of its peers in the Medical Devices & Instruments industry. This ratio, alongside the company's fair financial strength rating of 6 out of 10, suggests that Insulet's financial position is stable, yet there is room for improvement.
Profitability and Growth
Insulet has maintained profitability for 5 out of the past 10 years, boasting a revenue of $1.60 billion and an Earnings Per Share (EPS) of $1.71 over the last twelve months. Its operating margin of 8.81% ranks favorably against 64.44% of companies in its industry. The company's profitability rank of 6 out of 10 indicates a fair level of profitability.
Growth is a vital indicator of a company's valuation. Insulet's 3-year average annual revenue growth rate of 16.4% outperforms 71.09% of its industry counterparts. However, its 3-year average EBITDA growth rate of 8.1% is less impressive, ranking lower than 52.22% of similar companies.
ROIC vs WACC
Comparing Return on Invested Capital (ROIC) to the Weighted Average Cost of Capital (WACC) is another way to measure profitability. Insulet's ROIC over the past 12 months is 8.98, which is lower than its WACC of 11.38, indicating that the company may not be creating value for its shareholders as efficiently as possible.
Conclusion
In conclusion, Insulet (PODD, Financial) appears to be significantly undervalued based on our analysis. The company demonstrates fair financial health and profitability, with growth rankings that suggest potential for improvement. To gain a more detailed understanding of Insulet's financial trajectory, interested investors can explore its 30-Year Financials here.
To discover high-quality companies that may deliver above-average returns, please check out the GuruFocus High Quality Low Capex Screener.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
